Vertex Pharmaceuticals Incorporated (VRTX)
Nasdaq: VRTX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 1995
Grade7.0
◀ Past 7.3● Present 7.6▶ Future 5.9
Who owns Vertex Pharmaceuticals Incorporated
As filed with the SECHolders of 5% or more
3
Capital World Investors holds 10.1% of Common Stock, as its SCHEDULE 13G/A filed May 14, 2026 says.
Directors and officers
24
report now, of 37 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Capital World Investors
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock · 11.2% in Feb 13, 2025
Capital Research Global Investors
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock · 6.8% in Feb 12, 2026
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Fmr LLC
SCHEDULE 13G/A · filed Feb 12, 2025 · COMMON STOCK · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What VRTX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Alphine Immune Sciences Inc
A company bought · asset acquisition · owns, named in the 10-K filed Feb 13, 2026
16 subsidiaries in 4 countries, from the list filed with the 10-K filed Feb 13, 2026.
Insider tradesForm 4
94sales
0purchases
94sales on a scheduled plan
13people selling
$164Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window13 of 37 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Leiden Jeffrey M | Executive Chairman | 17 | $60.9M | 17 | 0 | $0 |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 9 | $28.4M | 9 | 0 | $0 |
| Kewalramani Reshma | CEO & President | 14 | $26.0M | 14 | 0 | $0 |
| Bozic Carmen | EVP and CMO | 10 | $11.3M | 10 | 0 | $0 |
| Wagner Charles F Jr | EVP, CO & FO | 3 | $10.8M | 3 | 0 | $0 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 8 | $6.5M | 8 | 0 | $0 |
| Mckechnie Duncan | EVP, Chief Commercial Officer | 5 | $5.7M | 5 | 0 | $0 |
| Biller Jonathan | EVP and Chief Legal Officer | 6 | $3.8M | 6 | 0 | $0 |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 5 | $3.6M | 5 | 0 | $0 |
| Bunnage Mark E. | EVP, Chief Scientific Officer | 5 | $3.0M | 5 | 0 | $0 |
| Liu Joy | EVP and Chief Legal Officer | 5 | $2.1M | 5 | 0 | $0 |
| Ambrose Kristen | SVP & Chief Accounting Officer | 5 | $2.0M | 5 | 0 | $0 |
| Bhatia Sangeeta N. | director | 2 | $300,000 | 2 | 0 | $0 |